CIR and 95% CI stratified by post-transplantation HCMV pp65-antigenemia in patients with grades II to IV acute GVHD. (A) CIR by post-transplantation pp65-antigenemia in all patients who developed grades II to IV acute GVHD (P < .0005). (B) CIR by post-transplantation pp65-antigenemia of patients who developed grades II to IV and survived free of relapse at day 100 after transplantation (P < .0005). Tick marks indicate patients surviving free of relapse or competing events.